Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Cyclica","sponsor":"Cyclica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroTheryX Partners with Cyclica to Launch NineteenGale Therapeutics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Cyclica","sponsor":"Cerevel Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cerevel Therapeutics and Cyclica Collaborate to Use Artificial Intelligence to Accelerate Discovery of Novel Medicines in Neuroscience","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"CANADA","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Cyclica","sponsor":"Structural Genomics Consortium","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyclica and the Structural Genomics Consortium Co-crystallize DCAF1, a Key Component in Proteasomal Degradation, With a Novel Ligand to Support Targeted Therapeutics Discovery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"CANADA","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Cyclica","sponsor":"Arctoris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyclica and Arctoris to Expand Partnership to Advance Drug Discovery Programs for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"},{"orgOrder":0,"company":"Cyclica","sponsor":"Recursion Pharma","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by Cyclica

    Menu

    Cyclica

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Cyclica

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities

              Details:

              Through the acquisition, Cyclica's two highly differentiated products in the digital chemistry space which will be integrated into the Recursion OS, including MatchMaker™, an AI-enabled deep learning engine that predicts the polypharmacology of small molecules and POEM™.

              Lead Product(s): Undisclosed

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Small molecule

              Partner/Sponsor/Collaborator: Recursion Pharma

              Deal Size: $40.0 million Upfront Cash: Undisclosed

              Deal Type: Acquisition May 08, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cyclica

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cyclica and Arctoris to Expand Partnership to Advance Drug Discovery Programs for Alzheimer's Disease

              Details:

              Cyclica’s platform and capabilities in combination with the biological assay development of Arctoris will enable us to yield meaningful results and advance research development for patients suffering from Alzheimers and other neurodegenerative diseases.

              Lead Product(s): Cyclosporine

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Arctoris

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership March 23, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cyclica

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cyclica and the Structural Genomics Consortium Co-crystallize DCAF1, a Key Component in Proteasomal Degradation, With a Novel Ligand to Support Targeted Therapeutics Discov...

              Details:

              As part of the initiative, the SGC and Cyclica examined three WDR proteins to discover small molecule binders using Cyclica’s proprietary deep learning platform to assess commercially available libraries for potential binders.

              Lead Product(s): Undisclosed

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Small molecule

              Partner/Sponsor/Collaborator: Structural Genomics Consortium

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership November 11, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cyclica

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cerevel Therapeutics and Cyclica Collaborate to Use Artificial Intelligence to Accelerate Discovery of Novel Medicines in Neuroscience

              Details:

              Cerevel will utilize Cyclica’s Ligand Express® and Ligand Design™ platforms to screen, identify, evaluate and optimize targets to develop neuroscience medicines.

              Lead Product(s): Undisclosed

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Small molecule

              Partner/Sponsor/Collaborator: Cerevel Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration July 27, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cyclica

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NeuroTheryX Partners with Cyclica to Launch NineteenGale Therapeutics

              Details:

              Under the initial stealth project, NeuroTheryX combined their phenotype-based drug discovery platform with Cyclica’s first-in-class proteome screening platform.

              Lead Product(s): Cannabinoid-based product

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Recipient: NineteenGale Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership March 19, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY